PRESS INFO

Kuehne+Nagel Group

Sinovac relies on Kuehne+Nagel’s pharma network for Covid-19 distribution

. Kuehne+Nagel handles first Sinovac Covid-19 vaccine export shipment . 768,000 vials of vaccine safely arrived in the Dominican Republic

Shanghai, CN, February 26, 2021 – Kuehne+Nagel successfully helped Sinovac Biotech Ltd., a leading biopharmaceutical company in (Nasdaq: SVA) fulfill its first Covid-19 vaccine shipment from , China to the Dominican Republic.

Sinovac is one of the global players in Covid-19 vaccine research and development. To date, the vaccine has been approved for emergency use or conditional marketing authorisation in more than 20 countries, including China, , , Turkey and Chile.

The pilot shipment containing 768,000 vials of Covid-19 vaccine was stored in active temperature-controlled containers and arrived safely in Santo Domingo, the capital of the Dominican Republic, on February 23, benefitting its citizens just before its Independence Day. The shipment was closely monitored and compliant with the most stringent standards to guarantee product integrity.

Helen Yang, General Manager of Sinovac Biotech (Hong Kong) Limited said: “The Dominican Republic is 14,000 kilometers away from our factory in Beijing. During the ongoing pandemic, there are very few Kuehne + Nagel International AG carriers connecting to this remote destination. However, Kuehne+Nagel responded to us with a feasible solution in just a short span of twelve Dominique Nadelhofer hours. Even during the Chinese New Year holidays, the Kuehne+Nagel Media Communication team was diligently preparing this shipment. We look forward to a Schindellegi, Switzerland collaborative partnership with Kuehne+Nagel.”

+41 (0)44 786 9526 dominique.nadelhofer@ Siewloong Wong, President of Kuehne+Nagel Asia Pacific said: “We kuehne-nagel.com couldn’t be prouder to having started shipments of Sinovac Covid-19

Kuehne + Nagel Limited vaccine. At Kuehne+Nagel, we leverage our global pharma & healthcare network and expertise to bring the Sinovac vaccine to the market. We Lily Ma truly appreciate the trust that Sinovac has bestowed upon us.” +86 (21) 2602 8782 [email protected]

Prior to this shipment, Kuehne+Nagel successfully fulfilled multiple crucial assignments for Sinovac, including an air charter from Beijing to Turkey for a door-to-door delivery of nearly a quarter-million flu . Kuehne+Nagel also helped with the shipment of to Guatemala in South America as well as making nucleic acid detection kits available to people in Indonesia.

With offices all over the world, 240 GxP-certified operations and more than 3,000 dedicated pharma & healthcare specialists, Kuehne+Nagel has the capacity, the ability and the responsibility to play a vital role in the global distribution of COVID-19 vaccine.

About Kuehne+Nagel With over 78,000 employees at 1,400 locations in over 100 countries, the Kuehne+Nagel Group is one of the world's leading logistics companies. Its strong market position lies in sea logistics, air logistics, road logistics and contract logistics, with a clear focus on integrated logistics solutions. www.kuehne-nagel.com

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal , 23-Valent Pneumococcal Polysaccharide (“PPV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand, foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China. For more information please see the Company’s website at www.sinovac.com.

Page 2